PAVmed (PAVM) to Release Quarterly Earnings on Tuesday

PAVmed (NASDAQ:PAVM) is set to post its quarterly earnings results before the market opens on Tuesday, August 13th. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

PAVmed (NASDAQ:PAVM) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.99) EPS for the quarter. The company had revenue of $1.01 million during the quarter.

PAVmed Price Performance

PAVM traded down $0.02 during midday trading on Tuesday, hitting $0.79. 10,401 shares of the company’s stock traded hands, compared to its average volume of 66,344. The company has a market cap of $7.45 million, a PE ratio of -0.08 and a beta of 0.65. The stock’s fifty day simple moving average is $0.98 and its 200-day simple moving average is $1.73. PAVmed has a one year low of $0.60 and a one year high of $9.00.

Analyst Upgrades and Downgrades

Separately, Lake Street Capital upgraded PAVmed to a “strong-buy” rating in a research note on Wednesday, May 15th.

PAVmed Company Profile

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.